Bradley Foster & Sargent Inc. CT Trims Stock Holdings in Henry Schein, Inc. (NASDAQ:HSIC)

Bradley Foster & Sargent Inc. CT reduced its holdings in shares of Henry Schein, Inc. (NASDAQ:HSIC) by 2.6% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 9,556 shares of the company’s stock after selling 260 shares during the quarter. Bradley Foster & Sargent Inc. CT’s holdings in Henry Schein were worth $613,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently bought and sold shares of the business. Norges Bank bought a new position in shares of Henry Schein in the fourth quarter worth $111,715,000. PNC Financial Services Group Inc. boosted its stake in Henry Schein by 5.6% in the 4th quarter. PNC Financial Services Group Inc. now owns 87,085 shares of the company’s stock worth $6,593,000 after purchasing an additional 4,591 shares during the period. Corient Private Wealth LLC grew its holdings in Henry Schein by 1.0% during the 4th quarter. Corient Private Wealth LLC now owns 55,741 shares of the company’s stock valued at $4,220,000 after buying an additional 542 shares in the last quarter. SageView Advisory Group LLC purchased a new position in Henry Schein during the 4th quarter valued at about $285,000. Finally, Hsbc Holdings PLC increased its position in shares of Henry Schein by 18.1% during the fourth quarter. Hsbc Holdings PLC now owns 267,587 shares of the company’s stock valued at $20,228,000 after buying an additional 41,087 shares during the period. 96.62% of the stock is owned by institutional investors.

Henry Schein Stock Performance

NASDAQ:HSIC opened at $72.54 on Friday. The company has a market capitalization of $9.29 billion, a price-to-earnings ratio of 24.51, a PEG ratio of 1.88 and a beta of 0.86. The business has a 50 day moving average of $69.77 and a 200 day moving average of $70.42. The company has a debt-to-equity ratio of 0.46, a current ratio of 1.55 and a quick ratio of 0.90. Henry Schein, Inc. has a 1-year low of $60.01 and a 1-year high of $82.63.

Henry Schein (NASDAQ:HSIC) last announced its quarterly earnings data on Tuesday, August 6th. The company reported $1.23 earnings per share for the quarter, topping analysts’ consensus estimates of $1.22 by $0.01. Henry Schein had a net margin of 2.82% and a return on equity of 13.19%. The firm had revenue of $3.10 billion during the quarter, compared to analyst estimates of $3.27 billion. During the same period in the previous year, the business posted $1.31 EPS. The business’s quarterly revenue was up .0% on a year-over-year basis. On average, sell-side analysts predict that Henry Schein, Inc. will post 4.75 earnings per share for the current fiscal year.

Insider Buying and Selling at Henry Schein

In other news, SVP Lorelei Mcglynn sold 21,035 shares of Henry Schein stock in a transaction dated Friday, September 6th. The stock was sold at an average price of $69.30, for a total value of $1,457,725.50. Following the transaction, the senior vice president now owns 71,833 shares in the company, valued at $4,978,026.90. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Company insiders own 1.14% of the company’s stock.

Analysts Set New Price Targets

HSIC has been the subject of a number of analyst reports. Evercore ISI cut their price objective on shares of Henry Schein from $72.00 to $70.00 and set an “in-line” rating for the company in a research report on Wednesday, August 7th. Robert W. Baird reduced their price target on shares of Henry Schein from $92.00 to $82.00 and set an “outperform” rating for the company in a research report on Wednesday, August 7th. JPMorgan Chase & Co. lowered their price objective on Henry Schein from $88.00 to $80.00 and set an “overweight” rating on the stock in a research report on Monday, August 12th. UBS Group reduced their target price on Henry Schein from $75.00 to $72.00 and set a “neutral” rating for the company in a research report on Wednesday, August 7th. Finally, Piper Sandler reaffirmed an “overweight” rating and issued a $86.00 price target on shares of Henry Schein in a report on Friday, June 21st. One investment analyst has rated the stock with a sell rating, six have assigned a hold rating, five have issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, Henry Schein currently has a consensus rating of “Hold” and an average target price of $77.10.

Henry Schein Profile

Henry Schein, Inc provides health care products and services to dental practitioners, laboratories, physician practices, and ambulatory surgery centers, government, institutional health care clinics, and other alternate care clinics worldwide. It operates through two segments, Health Care Distribution, and Technology and Value-Added Services.